8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Feb 6, 2026·SEC
Pyxis Oncology, Inc.(PYXS)Earnings, Financials & Key Ratios
PYXS•NASDAQ
Price updated Jun 11, 2026
AboutPyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$14M-14.2%
- EBITDA-$80M+7.6%
- Net Income-$80M-3.0%
- EPS (Diluted)-1.28+3.0%
- Gross Margin82.77%-14.7%
- EBITDA Margin-576.63%-7.7%
- Operating Margin-609.18%-9.9%
- Net Margin-574.55%-20.0%
- ROE-91.43%-45.7%
- ROIC-71.09%-37.1%
- Debt/Equity0.35+109.0%
PYXS Key Insights
Pyxis Oncology, Inc. (PYXS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 44.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PYXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PYXS Price & Volume
Pyxis Oncology, Inc. (PYXS) stock price & volume — 10-year historical chart
Loading chart...
PYXS Growth Metrics
Pyxis Oncology, Inc. (PYXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM16.56%
Return on Capital
10 Years-59.57%
5 Years-60.18%
3 Years-64.28%
Last Year-80.44%
PYXS Recent Earnings
Pyxis Oncology, Inc. (PYXS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (100%)
Q2 2026Latest
May 14, 2026EPS
$0.37
Est $0.35
-5.7%
Revenue
—
Est $19,440
Q2 2026
Mar 23, 2026EPS
$0.29
Est $0.35
+17.1%
Revenue
$11M
Est $125,000
+8730.4%
Q4 2025
Nov 3, 2025EPS
$0.35
Est $0.36
+2.8%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.30
Est $0.36
+16.7%
Revenue
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.37vs $0.35-5.7% | —vs $19,440 |
| Q2 2026 | Mar 23, 2026 | $0.29vs $0.35+17.1% | $11Mvs $125,000+8730.4% |
| Q4 2025 | Nov 3, 2025 | $0.35vs $0.36+2.8% | — |
| Q3 2025 | Aug 14, 2025 | $0.30vs $0.36+16.7% | $3M |
Based on last 12 quarters of dataView full earnings history →
PYXS Peer Comparison
Pyxis Oncology, Inc. (PYXS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TPST | 5.55M | 1.25 | -0.20 | -7.3% | 1.22 | |||
 AGIO | 1.71B | 28.72 | -4.03 | 48.03% | -6.4% | -34.11% | 0.05 | |
 MGNX | 254.89M | 4.01 | -3.40 | 0.78% | -44.79% | -147.8% | 1.92 | |
 SNDX | 1.58B | 17.91 | -5.44 | 6.28% | -112.01% | -256.66% | 5.36 | |
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare PYXS vs Peers
Pyxis Oncology, Inc. (PYXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PYXS Income Statement
Pyxis Oncology, Inc. (PYXS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 16.15M | 13.86M | 13.86M |
Revenue Growth % | - | - | - | - | - | - | -14.17% | - |
Cost of Goods Sold | 0 | 444K | 0 | 0 | 0 | 475K | 2.39M | 27K |
COGS % of Revenue | - | - | - | - | - | 2.94% | 17.23% | - |
Gross Profit | 0▲ 0% | -444K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 15.67M▲ 0% | 11.47M▼ 26.8% | 13.83M▲ 0% |
Gross Margin % | - | - | - | - | - | 97.06% | 82.77% | 99.81% |
Gross Profit Growth % | - | - | 100% | - | - | - | -26.81% | - |
Operating Expenses | 2.88M | 12.45M | 69.72M | 123.48M | 82.2M | 105.13M | 95.89M | 99.7M |
OpEx % of Revenue | - | - | - | - | - | 651.13% | 691.95% | - |
Selling, General & Admin | 1.66M | 3.85M | 18.66M | 37.35M | 32.61M | 25.42M | 22.19M | 20.02M |
SG&A % of Revenue | - | - | - | - | - | 157.44% | 160.15% | - |
Research & Development | 1.22M | 8.6M | 51.05M | 86.13M | 49.59M | 58.75M | 73.7M | 76.25M |
R&D % of Revenue | - | - | - | - | - | 363.85% | 531.79% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 20.96M | 0 | 1.61M |
Operating Income | -2.88M▲ 0% | -12.89M▼ 347.9% | -69.72M▼ 440.7% | -123.48M▼ 77.1% | -82.2M▲ 33.4% | -89.46M▼ 8.8% | -84.42M▲ 5.6% | -85.87M▲ 0% |
Operating Margin % | - | - | - | - | - | -554.07% | -609.18% | -619.61% |
Operating Income Growth % | - | -347.86% | -440.69% | -77.12% | 33.43% | -8.84% | 5.63% | - |
EBITDA | -2.77M | -12.45M | -69.07M | -122.77M | -80.27M | -86.48M | -79.91M | -81.45M |
EBITDA Margin % | - | - | - | - | - | -535.6% | -576.63% | -587.73% |
EBITDA Growth % | - | -349.13% | -454.78% | -77.75% | 34.62% | -7.74% | 7.6% | 21.95% |
D&A (Non-Cash Add-back) | 0 | 444K | 647K | 709K | 1.93M | 2.98M | 4.51M | 4.42M |
EBIT | -2.77M | -12.83M | -69.72M | -123.48M | -82.2M | -68.5M | -84.42M | -84.41M |
Net Interest Income | 107K | 66K | 23K | 2.76M | 6.63M | 7.04M | 3.61M | 2.83M |
Interest Income | 107K | 66K | 23K | 2.76M | 6.63M | 7.04M | 3.61M | 2.83M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 107K | 66K | -6.26M | 2.76M | 8.41M | 9.96M | 6.18M | 5.52M |
Pretax Income | -2.77M▲ 0% | -12.83M▼ 362.8% | -75.97M▼ 492.3% | -120.72M▼ 58.9% | -73.79M▲ 38.9% | -79.5M▼ 7.7% | -78.23M▲ 1.6% | -80.35M▲ 0% |
Pretax Margin % | - | - | - | - | - | -492.35% | -564.55% | -579.8% |
Income Tax | 0 | 0 | 0 | 0 | 0 | -2.16M | 1.39M | 1.39M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 2.72% | -1.77% | -1.72% |
Net Income | -2.77M▲ 0% | -12.83M▼ 362.8% | -75.97M▼ 492.3% | -120.72M▼ 58.9% | -73.79M▲ 38.9% | -77.33M▼ 4.8% | -79.62M▼ 3.0% | -81.73M▲ 0% |
Net Margin % | - | - | - | - | - | -478.95% | -574.55% | -589.8% |
Net Income Growth % | - | -362.77% | -492.26% | -58.89% | 38.87% | -4.8% | -2.96% | 14.17% |
Net Income (Continuing) | -2.77M | -12.83M | -75.97M | -120.72M | -73.79M | -77.33M | -79.62M | -81.73M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.08▲ 0% | -0.37▼ 376.2% | -2.53▼ 583.8% | -3.57▼ 41.1% | -1.85▲ 48.2% | -1.32▲ 28.6% | -1.28▲ 3.0% | -1.29▲ 0% |
EPS Growth % | - | -376.19% | -583.78% | -41.11% | 48.18% | 28.65% | 3.03% | 16.56% |
EPS (Basic) | -0.08 | -0.37 | -2.53 | -3.57 | -1.85 | -1.32 | -1.28 | - |
Diluted Shares Outstanding | 34.31M | 34.31M | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M | 63.47M |
Basic Shares Outstanding | 34.31M | 34.31M | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M | 63.47M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PYXS Balance Sheet
Pyxis Oncology, Inc. (PYXS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.7M | 8.1M | 278.67M | 186.61M | 124.6M | 132.44M | 72.11M | 45.57M |
Cash & Short-Term Investments | 19.69M | 8.08M | 274.74M | 179.29M | 119.3M | 126.93M | 66.86M | 42.49M |
Cash Only | 19.69M | 8.08M | 274.74M | 179.29M | 9.66M | 19.47M | 15.42M | 7.24M |
Short-Term Investments | 0 | 0 | 0 | 0 | 109.63M | 107.46M | 51.44M | 35.25M |
Accounts Receivable | 0 | 0 | 0 | 598K | 21K | 0 | 700K | 0 |
Days Sales Outstanding | - | - | - | - | - | - | 18.44 | 24.36 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 15K | 1.56M | 5.41M | 4.27M | 4.75M | 4.55M | 3.08M |
Total Non-Current Assets | 106K | 2.05M | 1.35M | 24.77M | 49.12M | 24.74M | 19.41M | 18.73M |
Property, Plant & Equipment | 76K | 1.94M | 1.24M | 24.77M | 24.81M | 22.14M | 19.41M | 18.73M |
Fixed Asset Turnover | - | - | - | - | - | 0.73x | 0.71x | 0.70x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 24.31M | 2.6M | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 30K | 109K | 109K | 0 | 0 | 0 | 0 | 0 |
Total Assets | 19.81M▲ 0% | 10.15M▼ 48.8% | 280.02M▲ 2658.6% | 211.38M▼ 24.5% | 173.73M▼ 17.8% | 157.18M▼ 9.5% | 91.52M▼ 41.8% | 64.3M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.10x | 0.15x | 0.14x |
Asset Growth % | - | -48.75% | 2658.56% | -24.51% | -17.81% | -9.52% | -41.77% | -181.25% |
Total Current Liabilities | 733K | 3.69M | 18.71M | 31.63M | 25.76M | 17.68M | 21.13M | 16.53M |
Accounts Payable | 491K | 1.08M | 11.95M | 7.1M | 3.9M | 4.86M | 10.88M | 4.99M |
Days Payables Outstanding | - | 885.37 | - | - | - | 3.73K | 1.66K | 118.43K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.69M | 1.76M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 7.66M | 0 | 0 | 0 |
Other Current Liabilities | 116K | 1.12M | 3.23M | 5.33M | 5.58M | 4.63M | 8.55M | 9.79M |
Current Ratio | 26.88x | 2.20x | 14.90x | 5.90x | 4.84x | 7.49x | 3.41x | 2.76x |
Quick Ratio | 26.88x | 2.20x | 14.90x | 5.90x | 4.84x | 7.49x | 3.41x | 2.76x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -118.4K |
Total Non-Current Liabilities | 21.95M | 22.11M | 0 | 18.92M | 22.26M | 18.75M | 16.98M | 16.5M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 16.98M | 0 |
Capital Lease Obligations | 6K | 165K | 0 | 18.92M | 20.1M | 18.75M | 0 | 68.82M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 2.16M | 0 | 0 | 0 |
Other Non-Current Liabilities | 21.94M | 21.94M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22.68M | 25.8M | 18.71M | 50.55M | 48.02M | 36.43M | 38.11M | 33.03M |
Total Debt | 15K | 780K | 165K | 18.92M | 21.33M | 20.2M | 18.67M | 18.26M |
Net Debt | -19.68M | -7.3M | -274.57M | -160.37M | 11.67M | 727K | 3.25M | 11.02M |
Debt / Equity | - | - | 0.00x | 0.12x | 0.17x | 0.17x | 0.35x | 0.58x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.22x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.14x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | -2.87M▲ 0% | -15.64M▼ 444.4% | 261.31M▲ 1770.3% | 160.82M▼ 38.5% | 125.7M▼ 21.8% | 120.75M▼ 3.9% | 53.41M▼ 55.8% | 31.27M▲ 0% |
Equity Growth % | - | -444.36% | 1770.27% | -38.46% | -21.84% | -3.94% | -55.77% | -229.07% |
Book Value per Share | -0.08 | -0.46 | 8.11 | 4.87 | 3.15 | 2.07 | 0.86 | 0.49 |
Total Shareholders' Equity | -2.87M | -15.64M | 261.31M | 160.82M | 125.7M | 120.75M | 53.41M | 31.27M |
Common Stock | 1K | 1K | 32K | 34K | 45K | 60K | 63K | 63K |
Retained Earnings | -2.92M | -15.74M | -91.72M | -212.44M | -286.23M | -363.56M | -443.18M | -466.45M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 63K | 170K | 53K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PYXS Cash Flow Statement
Pyxis Oncology, Inc. (PYXS) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.24M | -10.08M | -35.33M | -89.33M | -70.71M | -57.67M | -63.5M | -66.97M |
Operating CF Margin % | - | - | - | - | - | -357.19% | -458.23% | - |
Operating CF Growth % | - | -350.38% | -250.32% | -152.89% | 20.85% | 18.44% | -10.11% | -434.06% |
Net Income | -2.77M | -12.83M | -75.97M | -120.72M | -73.79M | -77.33M | -79.62M | -81.73M |
Depreciation & Amortization | 0 | 469K | 647K | 709K | 1.93M | 2.98M | 4.51M | 4.42M |
Stock-Based Compensation | 28K | 44K | 6.44M | 15.76M | 16.95M | 12.95M | 11.8M | 8.17M |
Deferred Taxes | 0 | 0 | 6.28M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -264K | -56K | 20.6M | 10.41M | -4.13M | 15.55M | -2.14M | 27K |
Working Capital Changes | 505K | 2.29M | 6.68M | 4.5M | -11.66M | -11.82M | 1.94M | 2.15M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 292K | 558K | 4.64M | -8.33M | -3.51M | 1.2M | 6.03M | 2.14M |
Cash from Investing | 0 | -1.48M | -590K | -6.4M | -104.85M | 8.15M | 58.86M | 59.41M |
Capital Expenditures | 0 | -1.48M | -540K | -6.4M | -6.73M | -237K | -9K | -9K |
CapEx % of Revenue | - | - | - | - | - | 1.47% | 0.06% | 0.06% |
Acquisitions | 0 | 0 | -50K | 0 | 6.66M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -50 | 0 | 0 | 0 | 0 | -107.31M |
Cash from Financing | 21.95M | 35K | 304.04M | 183K | 5.93M | 59.33M | 594K | 569K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 3K | 303.88M | 0 | 6.12M | 59.05M | 742K | 673K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -67K |
Other Financing | 21.95M | 32K | 167K | 183K | -193K | 280K | -148K | -104K |
Net Change in Cash | 19.72M▲ 0% | -11.53M▼ 158.5% | 268.13M▲ 2425.1% | -95.55M▼ 135.6% | -169.63M▼ 77.5% | 9.81M▲ 105.8% | -4.05M▼ 141.3% | -6.99M▲ 0% |
Free Cash Flow | -2.24M▲ 0% | -11.57M▼ 416.6% | -35.87M▼ 210.1% | -95.73M▼ 166.9% | -77.44M▲ 19.1% | -57.91M▲ 25.2% | -63.51M▼ 9.7% | -66.98M▲ 0% |
FCF Margin % | - | - | - | - | - | -358.66% | -458.3% | -483.3% |
FCF Growth % | - | -416.61% | -210.07% | -166.92% | 19.11% | 25.22% | -9.67% | -12.57% |
FCF per Share | -0.07 | -0.34 | -1.11 | -2.90 | -1.94 | -0.99 | -1.02 | -1.06 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.79x | 0.46x | 0.74x | 0.96x | 0.75x | 0.80x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 1K | 10K | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 17K | 48K | 164K | 0 | 0 |
PYXS Key Ratios
Pyxis Oncology, Inc. (PYXS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -61.85% | -57.19% | -51.51% | -62.75% | -91.43% | -135.6% |
| Return on Invested Capital (ROIC) | - | - | - | -89.46% | -51.84% | -71.09% | -94.43% |
| Gross Margin | - | - | - | - | 97.06% | 82.77% | 99.81% |
| Net Margin | - | - | - | - | -478.95% | -574.55% | -589.8% |
| Debt / Equity | - | 0.00x | 0.12x | 0.17x | 0.17x | 0.35x | 0.58x |
| FCF Conversion | 0.79x | 0.46x | 0.74x | 0.96x | 0.75x | 0.80x | 0.82x |
| Revenue Growth | - | - | - | - | - | -14.17% | - |
Related:PYXS Dividend History·PYXS Revenue History·PYXS Price History·PYXS P/E History·PYXS Financial Ratios·PYXS Institutional Holders
PYXS SEC Filings & Documents
Pyxis Oncology, Inc. (PYXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
PYXS Frequently Asked Questions
Pyxis Oncology, Inc. (PYXS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pyxis Oncology, Inc. (PYXS) reported $13.9M in revenue for fiscal year 2025.
Pyxis Oncology, Inc. (PYXS) saw revenue decline by 14.2% over the past year.
Pyxis Oncology, Inc. (PYXS) reported a net loss of $81.7M for fiscal year 2025.
Dividend & Returns
Pyxis Oncology, Inc. (PYXS) has a return on equity (ROE) of -91.4%. Negative ROE indicates the company is unprofitable.
Pyxis Oncology, Inc. (PYXS) had negative free cash flow of $67.0M in fiscal year 2025, likely due to heavy capital investments.